West Virginia MPJE (Pharmacy Jurisprudence) Practice Exam 2025 - Free MPJE Practice Questions and Study Guide

Question: 1 / 400

When is an Investigational New Drug (IND) submitted to the FDA?

After Phase I trials

After Phase II trials

After preclinical animal research indicates a relatively safe drug with a potential therapeutic use

An Investigational New Drug (IND) is not submitted to the FDA after Phase I, II, or III trials. It is typically submitted after preclinical animal research has been completed and indicates that the drug is relatively safe and has potential therapeutic use. This is because the IND application includes information about preclinical studies and their results. While Phase I, II, and III trials are important in the drug development process, they are primarily used to test the drug's safety and efficacy in humans. Therefore, the more accurate answer is C, after preclinical animal research is completed.

Get further explanation with Examzify DeepDiveBeta

After Phase III trials

Next Question

Report this question

Download West Virginia MPJE (Pharmacy Jurisprudence) Practice Exam PDF Study Guide
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy